New combo therapy hopes to tackle tough lymphoma

NCT ID NCT04161248

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About 40 participants will receive the treatment over several cycles, and researchers will monitor side effects and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax combined with Rituximab, Gemcitabine, and Dexamethasone
What this could lead to: If successful, this could point toward a more effective treatment option for patients with relapsed aggressive B-cell lymphoma.
What could go wrong: This is a very early (Phase 1) trial with only 40 participants, so the main goal is safety, not proof of effectiveness. The new combination may cause severe side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm diffuse large B-cell lymphoma follicular lymphoma lymphoplasmacytic lymphoma MALT lymphoma marginal zone lymphoma primary mediastinal large B-cell lymphoma T-cell/histiocyte rich large B cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, B-CELL

Contacts and locations

Locations

BCCA - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada
The Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.